TCR2 Therapeutics Inc. TCRR
Set alert
1.48 0.00 0.00%
At close · May 31
1.48 Day range 1.48
52-week range unavailable
- Open
- 1.58
- Prev close
- 1.48
- Mkt cap
- 58.11M
- Vol
- 3.75M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.48
- High
- 1.48
- Forward P/E
- -0.60
- Beta
- 1.93
- Short ratio
- 1.29
- Inst. own
- 54.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 11, 2023
- 50-d avg
- 1.69
- 200-d avg
- 1.56
- 1y target
- 6.43
2Y chart
Events in this range
- Mar 22, 2022Earnings: —; estimate -0.75; surprise —%
- May 12, 2022Earnings: —; estimate -0.74; surprise —%
- Aug 8, 2022Earnings: —; estimate -0.77; surprise —%
- Nov 8, 2022Earnings: —; estimate -0.83; surprise —%
- Jan 6, 2023Rating: Piper Sandler · — → Overweight
- Mar 7, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
- Mar 8, 2023Downgrade: Truist Securities · Buy → Hold
- Mar 9, 2023Downgrade: Jefferies · Buy → Underperform
- Mar 23, 2023Rating: EF Hutton · — → Hold
- Mar 23, 2023Earnings: —; estimate -0.8; surprise —%
- Mar 24, 2023Downgrade: Mizuho · Buy → Neutral
- May 11, 2023Earnings: —; estimate -0.76; surprise —%
Signals (52)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | May 31, 2023 | 3 years ago |
| SMA: Bearish | May 26, 2023 | 3 years ago |
| SMA: Bearish | May 26, 2023 | 3 years ago |
| MACD: Sell Signal | May 16, 2023 | 3 years ago |
| RSI: Overbought | May 5, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| RSI: Overbought | Apr 24, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 14, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 23, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 2, 2023 | 3 years ago |
| SMA: Bullish | Feb 28, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 7, 2023 | 3 years ago |
| RSI: Overbought | Jan 27, 2023 | 3 years ago |
| SMA: Bullish | Jan 11, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 29, 2022 | 3 years ago |
| RSI: Oversold | Dec 12, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 9, 2022 | 3 years ago |
| RSI: Oversold | Nov 21, 2022 | 3 years ago |
| RSI: Oversold | Nov 2, 2022 | 3 years ago |
| RSI: Oversold | Oct 27, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 4, 2022 | 4 years ago |
| RSI: Oversold | Sep 16, 2022 | 4 years ago |
| RSI: Oversold | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Aug 26, 2022 | 4 years ago |
| SMA: Bullish | Aug 24, 2022 | 4 years ago |
| SMA: Bearish | Aug 19, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 19, 2022 | 4 years ago |
| SMA: Bearish | Aug 18, 2022 | 4 years ago |
| RSI: Overbought | Aug 11, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 10, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 20, 2022 | 4 years ago |
| RSI: Overbought | Jul 6, 2022 | 4 years ago |
| SMA: Bullish | Jun 6, 2022 | 4 years ago |
| MACD: Buy Signal | May 31, 2022 | 4 years ago |
| MACD: Sell Signal | May 25, 2022 | 4 years ago |
| MACD: Buy Signal | May 3, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 6, 2022 | 4 years ago |
| SMA: Bearish | Mar 23, 2022 | 4 years ago |
| SMA: Bullish | Mar 22, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 24, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 23, 2022 | 4 years ago |
| RSI: Oversold | Feb 18, 2022 | 4 years ago |
| RSI: Oversold | Feb 3, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 1, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 18, 2022 | 4 years ago |
| RSI: Oversold | Jan 18, 2022 | 4 years ago |
| RSI: Oversold | Jan 12, 2022 | 4 years ago |
| RSI: Oversold | Jan 5, 2022 | 4 years ago |
| RSI: Oversold | Dec 3, 2021 | 4 years ago |
| RSI: Oversold | Nov 26, 2021 | 4 years ago |
| RSI: Oversold | Nov 22, 2021 | 4 years ago |
Key statistics
- Market cap
- 58.11M
- Enterprise value
- -46.22M
- Trailing P/E
- 0.00
- Forward P/E
- -0.60
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.57
- EPS (TTM)
- -4.20
- Beta
- 1.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -69.13M
- Total cash
- 110.31M
- Total debt
- 5.98M
- Return on equity
- -91.46%
- Shares outstanding
- 39.26M
- Short % of float
- 1.16%
- 50-day average
- 1.69
- 200-day average
- 1.56
Analyst view
Consensus: hold
Hold
Price target (mean) 6.43 +334.5% upside
Now 1.48
- Target (low)
- 1.72
- Target (mean)
- 6.43
- Target (high)
- 20.00
Next earnings
May 11, 2023
Expected May 11, 2023. Consensus EPS estimate -0.64.
Financials — quick view
TCRR Revenue — quarterly 0
TCRR Net income — quarterly -40.40M
TCRR EPS — quarterly -1.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2023 | Mar 1, 2023 | -0.76 | — | — | — |
| Mar 23, 2023 | Dec 1, 2022 | -0.80 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -0.83 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.77 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.74 | — | — | — |
| Mar 22, 2022 | Dec 1, 2021 | -0.75 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 2023 | Mizuho | down | Buy | Neutral |
| Mar 23, 2023 | EF Hutton | reit | — | Hold |
| Mar 9, 2023 | Jefferies | down | Buy | Underperform |
| Mar 8, 2023 | Truist Securities | down | Buy | Hold |
| Mar 7, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 6, 2023 | Piper Sandler | main | — | Overweight |
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tcr2.com
News
- 5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
- Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
- Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
- TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
- TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
- Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on TCRR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARDAMA ALFONSO QUINTAS | Officer | Sale | Dec 12, 2022 | 109,459 |
| GADICKE ANSBERT S. | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | May 21, 2023 | 0 |
| GIBSON NEIL W | Director | Sale | Mar 19, 2020 | 0 |
| HOFMEISTER ROBERT PH.D. | Officer | Conversion of Exercise of derivative security | Dec 21, 2020 | 45,850 |
| JUSTICE ANGELA | Officer | Sale | Dec 11, 2022 | 48,745 |
| MENZEL GARRY E | Chief Executive Officer | Sale | Dec 12, 2022 | 575,139 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MPM Asset Management, LLC | 10.32% | 4,050,865 | 6.00M | Mar 30, 2023 |
| Tang Capital Management, LLC | 8.66% | 3,399,745 | 5.03M | Mar 30, 2023 |
| BioImpact Capital LLC | 8.59% | 3,370,982 | 4.99M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.74% | 1,468,802 | 2.17M | Mar 30, 2023 |
| Newtyn Management, Llc | 2.59% | 1,015,920 | 1.50M | Mar 30, 2023 |
| Acadian Asset Management. LLC | 2.07% | 812,459 | 1.20M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 981,016 | 1.45M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.12% | 439,478 | 650.43K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.47% | 185,778 | 274.95K | Feb 27, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.38% | 148,400 | 219.63K | Dec 30, 2022 |
| iShares US Small-Cap Equity Factor ETF | 0.31% | 120,862 | 178.88K | Feb 27, 2023 |
| Collaborative Inv Ser Tr-Greenwich Ivy Long-Short Fd | 0.18% | 71,616 | 105.99K | Dec 30, 2022 |